Sogroya is gaining popularity among endocrinologists in the treatment of patients with growth failure. It's finally time to discuss the dynamics of Novo Nordisk's EPS changes. Earnings per share ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk's 2024 earnings exceeded estimates ... thanks to the launch of Sogroya, a once-weekly treatment for growth hormone deficiency. As for blood disorders, sales also grew by 3%, boosted ...